Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surotomycin vs Vancomycin in CDAD
NCT01597505Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2012
- Primary completion
- Mar 2015
- Modality
- Cyclic Peptides, Peptide Conjugates, Antimicrobial Peptides
01
Overview
Phase 3, randomised, double-blind trial of surotomycin in Clostridioides difficile infection (CDI) (2 arms), sponsored by Merck & Co. Primary endpoints: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment at Day 10, Percentage of Participants With at Least One Adverse Event at Day 50 and 1 more. Started May 2012; status: completed.
02
Drugs
surotomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT01597505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01597505.